HealthEquity (HQY)
(Delayed Data from NSDQ)
$79.56 USD
+2.47 (3.20%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $79.51 -0.05 (-0.06%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$79.56 USD
+2.47 (3.20%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $79.51 -0.05 (-0.06%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Zacks News
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Strength Seen in Agiliti (AGTI): Can Its 29.1% Jump Turn into More Strength?
by Zacks Equity Research
Agiliti (AGTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Surgery Partners (SGRY) Beats Q4 Earnings Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of 18.92% and 0.82%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Ambrx Biopharma Inc. (AMAM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Ambrx Biopharma Inc. (AMAM) and HealthEquity (HQY) have performed compared to their sector so far this year.
Quest Diagnostics (DGX) Boosts Oncology Portfolio With New Test
by Zacks Equity Research
Quest Diagnostics (DGX) debuts the MelaNodal Predict test in collaboration with SkylineDx.
Here's Why You Should Add HealthEquity (HQY) to Your Portfolio
by Zacks Equity Research
HealthEquity's (HQY) strength in HSA raises optimism about the stock.
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
Zacks Industry Outlook Highlights Elevance Health, Cencora and HealthEquity
by Zacks Equity Research
Elevance Health, Cencora and HealthEquity have been highlighted in this Industry Outlook article.
3 Medical Services Stocks to Buy Amid Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. ELV, COR and HQY are set to gain the most. However, staffing shortages continue to disrupt the growth trend.
Is HCA Healthcare (HCA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how HCA Healthcare (HCA) and HealthEquity (HQY) have performed compared to their sector so far this year.
HealthEquity, Inc. (HQY) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
HealthEquity (HQY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
HealthEquity (HQY) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Align (ALGN) Ailed by Macroeconomic Issues & Currency Headwind
by Zacks Equity Research
Foreign exchange continues to be a major headwind for Align (ALGN) due to a considerable percentage of its revenues coming from outside the United States.
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Globus Medical (GMED), backed by the NuVasive merger and its prominence in the musculoskeletal field.
Myriad's (MYGN) New Acquisition to Boost Precision Oncology Arm
by Zacks Equity Research
Myriad Genetics (MYGN) is set to acquire certain assets of IPG, including Precise Liquid, which is expected to be launched later this year.
Here's Why You Should Retain Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Chemed (CHE) on the strength of the VITAS Healthcare and Roto-Rooter segments.
Quest Diagnostics (DGX) and Fitbit Team Up for New Pilot Study
by Zacks Equity Research
Quest Diagnostics (DGX) partners with Fitbit to study the potential of wearable devices to improve metabolic health.
Penumbra (PEN) Rides on Vascular Arm Strength Amid FX Woes
by Zacks Equity Research
Penumbra's (PEN) Vascular business is demonstrating strong growth, banking on a rapid increase in sales of vascular thrombectomy products in the United States.
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) on strong uptake of the myAir app with AirSense11.
ELV or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. HQY: Which Stock Is the Better Value Option?
Abbott's (ABT) Innovations Aid, Macroeconomic Issues Stay
by Zacks Equity Research
Abbott (ABT) is successfully continuing the rollout of Alinity, the company's fully integrated and automated molecular diagnostics analyzer.
Here's Why Investors Should Retain Thermo Fisher (TMO) Stock
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) due to its series of new product launches and promising growth strategy.
Here's Why Investors Should Retain Bruker (BRKR) Stock Now
by Zacks Equity Research
Investors are optimistic about Bruker (BRKR) on solid prospects of BSI Nano group and raised guidance.
IDEXX (IDXX) Enhances Fecal Dx Antigen Testing Platform
by Zacks Equity Research
IDEXX's (IDXX) Fecal Dx antigen testing detects the most prevalent and clinically relevant intestinal parasites in dogs and cats.
Integer Holdings (ITGR) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.